HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Model Imperial

This article was originally published in The Rose Sheet

Executive Summary

Model Imperial: Executes forbearance agreement with its bank lenders to which it owes approximately $45 mil., the firm said April 10. Under the agreement, the lenders have postponed exercising default rights until Aug. 31, allowing the company "to attempt to restructure its business outside Chapter 11," Boca Raton-based Model Imperial said. The agreement also gives the wholesale fragrance distributor an opportunity to reduce operating expenses; "improve operations and administration through downsizing"; and negotiate a composition agreement with trade creditors. Model Imperial also has been delisted from NASDAQ effective April 10. On April 2, the company estimated that its 1995 net loss would exceed $20 mil., revising a net loss for the year previously estimated at between $7.5 mil. and $8.5 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel